Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CCX 140 (Primary)
  • Indications Focal segmental glomerulosclerosis
  • Focus Therapeutic Use
  • Acronyms LUMINA1
  • Sponsors ChemoCentryx

    • Most Recent Events

    • 05 Nov 2019 According to a ChemoCentryx media release, data from this study will be presented at the American Society of Nephrology (ASN) Kidney Week 2019.
    • 19 Aug 2019 Status changed from recruiting to active, no longer recruiting.
    • 05 Aug 2019 According to a ChemoCentryx media release, the last patient is expected to be randomized in mid-August and top line data anticipated in the first half of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top